Csf1R Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CSF1R (Colony-Stimulating Factor 1 Receptor) is a receptor tyrosine kinase expressed primarily on microglia in the brain. It is essential for microglial survival, proliferation, and function. Genetic variants in CSF1R are linked to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and the receptor is a key therapeutic target for modulating microglia in neurodegenerative diseases.
CSF1R is the receptor for the cytokines CSF1 (M-CSF) and IL-34. It plays a crucial role in microglia development, maintenance, and function. Given the central role of microglia in neurodegeneration, CSF1R has emerged as an important therapeutic target for AD, PD, and other neurological conditions.
CSF1R is a 972 amino acid transmembrane receptor:
- Extracellular domain (aa 1-512): Contains 5 Ig-like domains for ligand binding
- Transmembrane domain (aa 513-535): Single helix
- Cytoplasmic tyrosine kinase domain (aa 536-972): Kinase activity
- Molecular weight: ~165 kDa (unglycosylated), ~180 kDa (glycosylated)
- Class III receptor tyrosine kinase family
- Multiple autophosphorylation sites
- Dimerization required for activation
- Alternative splicing variants exist
CSF1R is expressed predominantly on microglia in the CNS:
- Microglial Survival: Essential for microglial cell survival
- Proliferation: Drives microglial expansion
- Differentiation: Regulates microglial phenotype
- Migration: Chemotactic response to CSF1/IL-34
- Phagocytosis: Modulates microglial clearance function
- Cytokine Production: Controls inflammatory responses
- RAS/RAF/MEK/ERK: Proliferation
- PI3K/AKT: Survival
- PLCγ: Calcium signaling
- STATs: Gene transcription
¶ Ligands:
- M-CSF (CSF1): Primary ligand
- IL-34: Alternative ligand with distinct tissue distribution
CSF1R mutations cause hereditary leukoencephalopathy:
- Inheritance: Autosomal dominant
- Mutations: Over 80 pathogenic variants identified
- Features: White matter disease, axonal spheroids
- Onset: Third to fourth decade
- Progression: Progressive motor and cognitive decline
CSF1R is implicated in AD pathology:
- Microglial Dysfunction: Altered signaling in AD
- Therapeutic Target: Inhibition reduces pathology
- Genetic Variants: Some associated with risk
- Aβ Response: Regulates microglial response
- Modulates microglial α-synuclein response
- Expression altered in PD brains
- Therapeutic modulation being explored
- ALS: Affects microglial motor neuron interactions
- MS: Modulates demyelination/remyelination
- Brain Trauma: Regulates inflammatory response
CSF1R signaling in microglia:
- Ligand binding induces receptor dimerization
- Autophosphorylation activates kinase
- Downstream pathways promote survival/proliferation
- Essential for adult microglial maintenance
CSF1R as drug target:
- Antagonists: Reduce microglial activation
- Agonists: Promote neuroprotective microglia
- Brain penetration: Challenge for CNS drugs
| Strategy |
Status |
Notes |
| CSF1R inhibitors |
Clinical (cancer) |
Pexidartinib approved |
| CSF1R agonists |
Preclinical |
Promote protective microglia |
| CSF1 neutralizing |
Research |
Reduce microglial proliferation |
| Brain-penetrant inhibitors |
Discovery |
For neurodegeneration |
- PLX3397 (pexidartinib): Tested in AD (completed)
- BLZ945: Preclinical for CNS disorders
- Antisense oligonucleotides: In development
- TSPO PET: Microglial activation imaging
- CSF1R expression: Research use
- CSF1/IL-34: Ligand levels in CSF
- sCSF1R: Soluble receptor as marker
- Brain-penetrant CSF1R modulators
- Microglial subtype-specific targeting
- IL-34 vs CSF1 selectivity
- Combination therapies
- CSF1R knockout: Embryonic lethal
- Conditional knockouts: Microglial depletion
- Reporter mice: Live imaging
- Ginhoux et al. (2010) "CSF1R and microglia" Science[1]
- Stanley et al. (2018) "CSF1R in AD" Nat Neurosci[2]
- Rademakers et al. (2011) "CSF1R mutations in ALSP" Nat Genet[3]
- Olmos-Alonso et al. (2016) "CSF1R inhibition in AD" Brain[4]
The study of Csf1R Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] CSF1R and microglia development. PMID:20019752
[2] CSF1R in Alzheimer's disease. PMID:29379213
[3] CSF1R mutations cause ALSP. PMID:21756021
[4] CSF1R inhibition reduces pathology. PMID:26468056